EV/EBITDA Multiple: ARCA Bio (ABIO)

Brandmark of ARCA Biopharma Inc (ABIO)

ARCA Biopharma (ABIO) operates as a biotech hub where development depends on FDA verdicts and the success of clinical trials. The company creates cutting-edge medications to combat heart pathologies, planning to monetize innovations in atrial fibrillation therapy. This share price chart with the metric demonstrates the issuer's financial condition. Stable demand for patented cardiac drugs is ensured by the long-term necessity of supportive patient treatment.

ABIO (ARCA Biopharma, Inc.) Business Value to Operating Income Before Depreciation history from 07/04/2022 to 11/14/2026

Analytical breakdowns for ARCA Biopharma

- current price and projected stock value:
Stock Price ARCA Biopharma|ABIO - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization ARCA Biopharma|ABIO - Enterprise Value
- issuer book value statistics:
Accounting Value per Share ARCA Biopharma|ABIO - Accounting Value of Company|Market Capitalization to Book Value Ratio arcabio.com|ABIO - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital ARCA Biopharma|ABIO - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity ARCA Biopharma, Inc.|ABIO - Company Cumulative Debt|Debt to Book Capitalization Ratio ARCA Biopharma|ABIO - Long-Term Liabilities|Company Short-Term Debts ARCA Biopharma|Quick Ratio arcabio.com
- net income and valuation multiples indicators:
ABIO - Net Profit|Expected Profit ARCA Biopharma|ABIO - Company Value to Net Income|Future Price to Earnings ARCA Biopharma|ABIO - Price/Earnings to Growth Multiple|EV/EBITDA Multiple ARCA Biopharma|ABIO - Operating profit EBITDA|Net earnings per share (EPS TTM) ARCA Biopharma|ABIO - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth arcabio.com|ABIO - Earnings per share growth in current year|Earnings growth forecast for next year ARCA Biopharma
- company sales and revenue statistics:
ABIO - Company Gross Revenue|Company Projected Revenue ARCA Biopharma, Inc.|ABIO - Price to Sales|Forward P/S Multiple ARCA Biopharma Inc
Initial company analysis:ABIO (ARCA Biopharma)
Product sample of ARCA Biopharma, Inc.

ARCA Biopharma (ABIO) is undergoing a phase of shifting its operational focus and integrating new biotechnological assets. The enterprise value to EBITDA ratio allows for an assessment of the business's real value by excluding the impact of debt loads and tax regimes. By analyzing the EV/EBITDA multiple trend, an investor can determine whether the current share price results from undervaluation or is a sign of the company's systemic decline.

Direct competitors

EV/EBITDA Multiple REGN (Regeneron Corp)|Business Value to Operating Income Before Depreciation IRTC|LNTH: Enterprise Value to EBITDA Ratio|Company Value to EBITDA Mineralys|HTFL (HeartFlow Corp) - Enterprise Value to EBITDA Ratio|Kestra - Business Value to Operating Income Before Depreciation|ESPR (esperion.com) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation AMRN (Amarin)|Enterprise Value to EBITDA Ratio AVR (Anteris)|TNYA (Tenaya Therapeutics Inc) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple CVRX (CVRx Inc)|MIST: Enterprise Value to Operating Income Before Depreciation|CRDL: Enterprise Value to EBITDA Ratio|HeartBeam (BEAT) - Enterprise Value to EBITDA Ratio|Tenax Therapeutics, Inc. (TENX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation ADGM|BCDA (BioCardia Inc) - EV/EBITDA Multiple|VTAK: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acasti Pharma Inc (ACST)|AVTE - Company Value to EBITDA|EV/EBITDA Multiple VERV (Verve Therapeutics, Inc.)|Business Value to Operating Income Before Depreciation WINT